Dr. Gary Birnbaum, retired MCN MS specialist, offers updates about Multiple Sclerosis research on his new blog: www.MSResearchUpdate.com
WA21092 (“Opera”)
Study Overview
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif ®) In Patients with Relapsing Multiple Sclerosis
Study Duration–96 Weeks
Phase-III
Enrollment Closed
Principal Investigator
Sponsor
F.Hoffmann-La Roche Ltd
Research Contact
If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.
109MS401 (“ESTEEM”)
Study Overview
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis.
Principal Investigator
Sponsor
Biogen Idec
Research Contact
If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.
Protocol No.: CLR_09_21
Study Overview
A Placebo-Controlled Randomized Withdrawal Evaluation of the Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects with Spasticity Due to Multiple Sclerosis.
Principal Investigator
Sponsor
Sun Pharmaceuticals
Research Contact
If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.
105MS401 (“POP”)
Study Overview
Plegridy™ (peginterferon β 1a) Real World Effectiveness and Safety Observational Program.
Principal Investigator
Sponsor
Biogen Idec
Research Contact
If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.
TV5600-CNS-200006: ARPEGGIO
Study Overview
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients with Primary Progressive Multiple Sclerosis.
Principal Investigator
Sponsor
Teva Pharmaceuticals
Research Contact
If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.
TV44400-CNS-40083 (CONFIDENCE)
Study Overview
A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous Injections of Copaxone® (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily.
Principal Investigator
Research Contact
If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.
Alkermes ALK8700-A301 (EVOLVE)
Study Overview
A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis.
Principal Investigator
Research Contact
If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.
OBS14527 Sanofi/Genzyme “LEM-COG”:
A Prospective 24-Month Observational Study to Evaluate Neurocognitive Function and Safety in Patients with Relapsing Multiple Sclerosis Who Are Initiating LEMTRADA® Treatment in Routine Clinical Practice. Enrollment closed.
Principal Investigator
MA30143 “ENSEMBLE”:
An open-label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis. Enrollment closed.
Principal Investigator
OBS13434 Sanofi/Genzyme “PASS”:
A PROSPECTIVE, MULTICENTER, OBSERVATIONAL POST-AUTHORIZATION SAFETY STUDY TO EVALUATE THE LONG TERM SAFETY PROFILE OF LEMTRADA® (ALEMTUZUMAB) TREATMENT IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS. Enrollment closed.
Principal Investigator
OBS14448 Sanofi/Genzyme “PRO-ACT”:
A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA® Treatment In Patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modifying Therapy. Enrollment closed.
Principal Investigator
CFTY720D2403 Novartis “PASSAGE”
Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy. Enrollment closed.
Principal Investigator
109MS401 Biogen Idec “ESTEEM”
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM). Enrollment closed.
Principal Investigator
DWA21092 Roche “OPERA”
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate The Efficacy and Safety of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif ®) In Patients With Relapsing Multiple Sclerosis (96 weeks). Enrollment closed
Principal Investigator
CBAF312A2304 Novartis “EXPAND”
A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis (SPMS). Enrollment closed
Principal Investigator
RPC01-3001 Receptos “DAYBREAK”
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis. Enrollment closed
Principal Investigator
BN29739 Roche/Genzyme “VELOCE”
A PHASE IIIB, MULTICENTER, RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL STUDY TO EVALUATE THE EFFECTS OF OCRELIZUMAB ON IMMUNE RESPONSES IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS. Enrollment closed
Principal Investigator
SP12 “MedDay 229829”
Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study. Enrollment closed.
Principal Investigator
Corrona MS Registry
Corrona Multiple Sclerosis (MS) Registry. The Corrona MS Registry is a prospective, non-interventional, research study for patients with MS under the care of a board-certified neurologist. Currently enrolling
Principal Investigator
Please contact Dr. Calkwood’s Clinical Research Coordinator at 763-302-4175.
215MS202 “AFFINITY”:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies. Enrollment closed.
Principal Investigator
101MS329 “NOVA”
A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab standard Interval Dosing (SID) in Relation to Continued SID Treatment. Enrollment closed.
Principal Investigator
COMB157G2399 “ALITHIOS”
An open label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis. Enrollment closed.
ADS-AMT-MS301
A 3-ARM, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT. Enrollment closed.
Principal Investigator
ADS-AMT-MS303
A MULTICENTER, OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENT. Enrollment closed.